The latest episode of Plastic Surgery Untold kicks off Octane 2026 with an in depth conversation on the rapidly evolving world of weight loss, wellness, GLP medications, and peptides featuring Dr. Jonathan Kaplan, founder of DrWell. As demand for medical weight loss continues to grow, this episode breaks down what providers and patients actually need to understand to stay safe, compliant, and effective.

Dr. Kaplan shares how DrWell helps physicians navigate the increasingly complex wellness landscape, from pharmacy sourcing and regulatory compliance to advertising restrictions and medication access. With new GLP formulations, oral options, and peptides entering the market quickly, this discussion focuses on separating what is legitimate from what puts licenses and patient safety at risk.

Key takeaways from this episode include

How GLP medications, oral options, and injectables differ in real world effectiveness
Why LegitScript certification matters for advertising and compliance
The risks of research grade and veterinary use medications
What providers should know about 503A pharmacies and compounded formulations
Why peptides are expected to grow significantly in 2026
How wellness programs fit into surgical planning and long term patient outcomes

This episode offers a clear look at where weight loss and wellness are headed in 2026, what innovations are coming next, and how responsible oversight protects both patients and providers. If you are navigating GLPs, peptides, or wellness integration in aesthetics, this conversation provides critical context for what is changing and what to watch closely.

Listen to the latest episode of Plastic Surgery Untold from Octane 2026 anywhere you get your podcasts, or watch the full conversation on YouTube.